SANJAY MATHEW to Young Adult
This is a "connection" page, showing publications SANJAY MATHEW has written about Young Adult.
Connection Strength
0.674
-
Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):267-276.
Score: 0.085
-
Impulsivity and Suicidal Behavior. Curr Top Behav Neurosci. 2020; 47:179-195.
Score: 0.059
-
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26.
Score: 0.055
-
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
Score: 0.054
-
Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. J Affect Disord. 2016 Jan 15; 190:414-423.
Score: 0.044
-
Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012 Sep; 25(9):1073-87.
Score: 0.034
-
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9.
Score: 0.032
-
Comparing the effects of ECT and intravenous ketamine in psychiatric patients with major depressive episodes. J Affect Disord. 2025 Nov 15; 389:119727.
Score: 0.022
-
Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia. Mol Psychiatry. 2025 Aug; 30(8):3686-3694.
Score: 0.021
-
Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial. Biol Psychiatry. 2025 Oct 01; 98(7):568-577.
Score: 0.021
-
Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
Score: 0.020
-
Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
Score: 0.020
-
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
Score: 0.018
-
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
Score: 0.015
-
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
Score: 0.014
-
Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Arch Clin Neuropsychol. 2019 Jun 01; 34(4):539-547.
Score: 0.014
-
Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255.
Score: 0.014
-
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
Score: 0.014
-
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280.
Score: 0.014
-
DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clin Epigenetics. 2018 11 03; 10(1):136.
Score: 0.014
-
The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746.
Score: 0.012
-
Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. Eur Arch Psychiatry Clin Neurosci. 2017 Oct; 267(7):697-707.
Score: 0.012
-
Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. Bull Menninger Clin. 2016; 80(3):187-212.
Score: 0.011
-
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9.
Score: 0.011
-
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
Score: 0.011
-
A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. J Neuropsychiatry Clin Neurosci. 2015; 27(2):93-103.
Score: 0.010
-
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014 Jun 21; 15:240.
Score: 0.010
-
Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. J Psychiatr Res. 2014 Oct; 57:51-7.
Score: 0.010